Conditions: Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Oropharyngeal Cancer
Interventions: Drug: Utomilumab; Biological: ISA101b
Sponsors: M.D. Anderson Cancer Center; ISA Pharmaceuticals B.V.; Pfizer
Not yet recruiting - verified August 2017
http://ift.tt/2vkF3DK
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: June 2018 Source: Acta Biomaterialia, Volume 73 https://ift.tt/2kBbISt
-
http://bit.ly/2SylJiJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου